Has the U.S. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 37.0x which is lower than its 3-year average PE of 54.1x. The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 5.7x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 15 Jun 2026	US$2.4t	US$425.3b	US$66.0b	15.2x	37x	5.7x
Wed, 13 May 2026	US$2.2t	US$424.0b	US$65.8b	15.6x	33.7x	5.2x
Fri, 10 Apr 2026	US$2.3t	US$405.9b	US$72.5b	17.2x	31.7x	5.7x
Sun, 08 Mar 2026	US$2.3t	US$406.1b	US$71.9b	18.8x	32x	5.7x
Tue, 03 Feb 2026	US$2.3t	US$405.1b	US$73.9b	20.7x	31.1x	5.7x
Thu, 01 Jan 2026	US$2.3t	US$402.6b	US$71.5b	19.8x	31.6x	5.6x
Sat, 29 Nov 2025	US$2.3t	US$402.7b	US$71.4b	20.6x	31.6x	5.6x
Mon, 27 Oct 2025	US$1.9t	US$389.2b	US$63.5b	17.7x	29.7x	4.8x
Wed, 24 Sep 2025	US$1.8t	US$387.9b	US$60.9b	18.4x	29x	4.6x
Fri, 22 Aug 2025	US$1.8t	US$387.8b	US$61.0b	19.7x	28.7x	4.5x
Sun, 20 Jul 2025	US$1.7t	US$384.0b	US$62.1b	17.7x	28x	4.5x
Tue, 17 Jun 2025	US$1.8t	US$382.7b	US$61.2b	18.3x	29.1x	4.7x
Thu, 15 May 2025	US$1.7t	US$382.6b	US$61.1b	16.6x	27.1x	4.3x
Sat, 12 Apr 2025	US$1.6t	US$380.0b	US$40.6b	15.5x	39.6x	4.2x
Mon, 10 Mar 2025	US$1.9t	US$381.1b	US$39.2b	16.5x	49.1x	5.1x
Wed, 05 Feb 2025	US$1.9t	US$375.6b	US$38.5b	18.3x	48x	4.9x
Fri, 03 Jan 2025	US$1.8t	US$369.3b	US$31.3b	16.5x	57.1x	4.8x
Sun, 01 Dec 2024	US$1.9t	US$373.8b	US$30.6b	19.4x	61x	5x
Tue, 29 Oct 2024	US$2.0t	US$365.3b	US$23.7b	18.1x	83.2x	5.4x
Thu, 26 Sep 2024	US$2.0t	US$364.2b	US$25.3b	18.4x	80.3x	5.6x
Sat, 24 Aug 2024	US$2.0t	US$362.1b	US$21.8b	17.9x	93.7x	5.6x
Mon, 22 Jul 2024	US$2.0t	US$356.5b	US$13.1b	15.9x	149.1x	5.5x
Wed, 19 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.5x	137.3x	5.4x
Fri, 17 May 2024	US$1.9t	US$358.3b	US$14.0b	18.3x	134.9x	5.3x
Sun, 14 Apr 2024	US$1.8t	US$355.1b	US$23.9b	21.4x	76.5x	5.2x
Tue, 12 Mar 2024	US$1.9t	US$355.3b	US$22.4b	22.4x	83.2x	5.2x
Thu, 08 Feb 2024	US$1.8t	US$354.8b	US$23.1b	28.5x	79.4x	5.2x
Sat, 06 Jan 2024	US$1.7t	US$375.2b	US$33.8b	27.5x	51.7x	4.7x
Mon, 04 Dec 2023	US$1.7t	US$375.2b	US$33.9b	27.2x	48.7x	4.4x
Wed, 01 Nov 2023	US$1.6t	US$383.5b	US$46.5b	13.6x	34.3x	4.2x
Fri, 29 Sep 2023	US$1.7t	US$381.8b	US$43.7b	18.5x	37.8x	4.3x
Sun, 27 Aug 2023	US$1.8t	US$381.6b	US$44.1b	20.5x	40.2x	4.6x
Tue, 25 Jul 2023	US$1.7t	US$394.3b	US$60.5b	18.6x	28.6x	4.4x
Thu, 22 Jun 2023	US$1.7t	US$392.8b	US$60.1b	18.9x	29x	4.4x


US Market	0.50%
Healthcare	0.92%
Pharma	0.87%
Pharma	0.87%

Company	Last Price	7D	1Y	Valuation
JNJ Johnson & Johnson	US$240.87	3.8% +US$21.0b	55.2%	PE27.6x
PFE Pfizer	US$26.21	2.3% +US$3.4b	7.4%	PE20x
BMY Bristol-Myers Squibb	US$57.13	2.8% +US$3.2b	17.4%	PE16x
TEVA Teva Pharmaceutical Industries	US$34.63	4.1% +US$1.6b	97.9%	PE25.8x
AXSM Axsome Therapeutics	US$255.17	8.5% +US$1.0b	150.9%	PS18.5x

Announcement • Jun 09

Corcept Therapeutics Incorporated Presents New Data from Catalyst and Momentum Trials At American Diabetes Association’s 86Th Scientific Sessions

Corcept Therapeutics Incorporated announced the presentation of new data from its CATALYST and MOMENTUM trials at the American Diabetes Association’s 86th Scientific Sessions. In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide. The CATALYST trial screened 1,057 patients with difficult-to-control type 2 diabetes (HbA1c of 7.5 – 11.5% despite receiving multiple glucose-lowering medications) and found that 24% had hypercortisolism (cortisol levels of greater than 1.8 µg/dL in the 1 mg dexamethasone suppression test (DST)). In CATALYST’s treatment phase, 136 of the patients who had been found to have hypercortisolism were randomized 2:1 to receive either Korlym or placebo for 24 weeks. Patients who received Korlym exhibited a clinically meaningful and statistically significant reduction in HbA1c (1.3%), and clinically meaningful reductions in body weight, body mass index and waist circumference. The most common adverse events (greater than 10%) were hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea and dizziness. The data presented at ADA described treatment outcomes in the 71 patients in CATALYST who were taking GLP-1 receptor agonists or the GLP-1/GIP agonist tirzepatide. In this group, patients who received Korlym exhibited numerically greater benefit than the overall study population with reductions in HbA1c (1.7%), body weight (6.1 kg), body mass index (2.0 kg/m2) and waist circumference (6.5 cm), compared to patients who received placebo (all nominal p-values less than 0.04). Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension. At ADA, Corcept also presented late-breaking data from its MOMENTUM trial, which screened 1,086 patients with resistant hypertension (as defined by the American Heart Association’s criteria) and found that 27.3% of them had hypercortisolism. The prevalence of hypercortisolism was even higher in patients who had hemoglobin A1c (HbA1c) of 7.5% or higher and were taking 3 or more blood pressure medicines: 36.6% in CATALYST and 32.6% in MOMENTUM. CATALYST is the largest and most rigorous trial ever conducted to determine the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and assess the effect of treating patients found to have hypercortisolism with a cortisol modulator. The initial prevalence phase of the trial screened 1,057 patients with difficult-to-control type 2 diabetes (i.e., patients with HbA1c greater than 7.5% despite receiving multiple glucose-lowering medications, including best-in-class therapies such as GLP-1 and GLP-1/GIP agonists) at 36 sites in the United States. Based on results from a standard 1-mg dexamethasone suppression test, 24% of the patients screened were found to have hypercortisolism and were eligible to enter the trial’s treatment phase, where they were randomized, 2:1, to receive either Korlym or placebo for 24 weeks. One hundred thirty-six patients enrolled in the treatment phase. MOMENTUM was the largest trial ever conducted to assess the prevalence of hypercortisolism in patients with resistant hypertension. A total of 1,086 patients were screened at 50 sites in the United States. All patients had resistant hypertension as defined by the American Heart Association’s criteria (systolic blood pressure greater or equal to 130 mmHg despite taking 3 or more blood-pressure lowering medications, including a diuretic, or taking 4 or more blood-pressure lowering medications). Using a simple, standardized 1-mg dexamethasone suppression test (DST), 27% of these patients were found to have hypercortisolism. Hypercortisolism, also known as Cushing’s syndrome, is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be fatal if not treated effectively. Cardiovascular events are the most common cause of death among patients with hypercortisolism. Recent research shows that endogenous hypercortisolism is more prevalent than previously believed. KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Limitations of use: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a nonhormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential. Contraindications include pregnancy; patients taking simvastatin or lovastatin and CYP3A substrates with narrow therapeutic ranges; patients receiving systemic corticosteroids for lifesaving purposes; women with a history of unexplained vaginal bleeding or endometrial hyperplasia with atypia or endometrial carcinoma; patients with known hypersensitivity to mifepristone or to any of the product components. Adrenal insufficiency: Patients should be closely monitored for signs and symptoms of adrenal insufficiency. Hypokalemia should be corrected prior to treatment and monitored for during treatment. Measure serum potassium 1-2 weeks after starting or increasing the Korlym dose, and periodically thereafter. Mifepristone-induced hypokalemia should be treated with potassium supplementation based on severity. If hypokalemia persists despite potassium supplementation, consider adding mineralocorticoid antagonists. Vaginal bleeding and endometrial changes: Women may experience endometrial thickening or unexpected vaginal bleeding. Use with caution if the patient also has a hemorrhagic disorder or is on anticoagulant therapy.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Johnson & Johnson Innovative Medicine Presents Results From Phase 2/3 ENERGY Study Demonstrating IMAAVY (Nipocalimab-Aahu) Durable Hemoglobin Response and Rapid Onset of Effect in Warm Autoimmune Hemolytic Anemia

Pomerantz Law Firm Announces Filing of Class Action Against Regencell Bioscience Holdings Limited and Certain Officers

Merck Receives Fda Approval for KEYTRUDA, KEYTRUDA QLEX, and WELIREG Combinations for Adjuvant Treatment of Clear Cell Renal Cell Carcinoma

Jason Pernell to Terminate Employment His Position of President of Trulieve Cannabis Corp., Effective June 11, 2026

Jazz Pharmaceuticals plc Provides Update on Zepzelca Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer

Enliven Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $399.998279 million.

Axsome Therapeutics Expands With Auvelity Alzheimer’s Launch and New Major Depression Study

Pharvaris N.V., Annual General Meeting, Jun 26, 2026

Perrigo Company: Expected Improvement In Latter Part Of FY26 Doing Little For Investor Sentiment

Amneal Pharmaceuticals to Acquire Kashiv and Expand Biosimilars After Strong Q1 Results

Bristol Myers Squibb Sees FDA Priority Reviews for Camzyos and Myeloma Therapies as Patent Risks Grow

Teva Reports Long-Term Efficacy Data for AUSTEDO in Tardive Dyskinesia Treatment

Corcept Therapeutics Incorporated Presents New Data from Catalyst and Momentum Trials At American Diabetes Association’s 86Th Scientific Sessions

PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing

Omeros: Launch Traction Encouraging, But Risk/Reward Looks Balanced (Initiating Hold)